pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ddavp
drug
save

desmopressin acetate

Marketedupdated 3mo ago
by Ferring Pharmaceuticals Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval4 co-mentions · 2 sources
  • drugDESMODA4 co-mentions · 3 sources
  • companyApotex Corp1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources
  • tagDrug Shortage1 co-mentions · 1 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

all catalysts(1)

approval · 1
Feb 25, 2026
approval
$ETON43.67-2.09%
6mo ago
DESMODA (DESMOPRESSIN ACETATE) — FDA approval
desmopressin acetate
→

Patent cliff

source: FDA Orange Book
first barrier falls
May 21, 2029
~2.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

  • Apr 3, 2044formulationUS 12214010
  • Apr 3, 2044formulationUS 12343372
  • Jun 15, 2030method-of-use (U-3431)US 114199143.8y
  • Jun 15, 2030method-of-use (U-3431)US 114199143.8y
  • Jun 15, 2030formulationUS 120901903.8y
  • Jun 15, 2030formulationUS 120901903.8y
  • Jun 15, 2030formulationUS 95393023.8y
  • Jun 15, 2030formulationUS 95393023.8y
  • Apr 13, 2030method-of-use (U-2326)US 99748263.7y
  • Apr 13, 2030method-of-use (U-2327)US 99748263.7y
  • May 21, 2029method-of-use (U-2327)US 101371672.8y
  • May 21, 2029method-of-use (U-2327)US 110204482.8y
  • May 21, 2029method-of-use (U-2327)US 119639952.8y
  • May 21, 2029method-of-use (U-2327)US 119639952.8y

News(0)

no news has mentioned this drug yet

brand
Ddavp
generic
desmopressin acetate
MOA
12.1 Mechanism of Action Desmopressin acetate’s primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine concentration. By influencing the permeability of the renal tubules, V2 receptors help maintain the body’s water balance and overall homeostasis.
indication
Diabetes Insipidus
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?